| Description |
1 online resource |
| Series |
SAGE business cases |
|
SAGE business cases
|
| Summary |
At the beginning of the COVID-19 pandemic, Moderna Inc. jumped into the pharmaceutical race for a vaccine. Moderna Inc., a biotech pharmaceutical company founded in 2010 in Cambridge, Massachusetts, focuses on research and manufacturing vaccines using messenger RNA (mRNA) technology. As the pandemic continues, Moderna faces issues regarding its intellectual property and patents. Moderna must find strategies to manage and protect their intellectual properties in a focused niche of mRNA vaccines and therapeutics while balancing their ethical obligation to help as many people as possible as quickly as possible. Students are invited to think through various tactics that Moderna Inc. can use to manage and protect its intellectual property and determine an optimal strategy for the company post-pandemic |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Description based on XML content |
| Subject |
Intellectual property -- Case studies
|
|
Vaccines -- Case studies
|
|
Intellectual property.
|
|
Vaccines.
|
| Genre/Form |
Case studies.
|
| Form |
Electronic book
|
| ISBN |
9781529793208 |
|
1529793203 |
|
